Although these TRAIL-engineered MSCs infiltrated into tumor tissue in vivo, they did not significantly modify neuroblastoma progress in murine models, indicating that MSCs could be applied to deliver therapeutic agents in neuroblastoma patients, whereas more effective biopharmaceuticals should be utilized instead of TRAIL (184). The gene discussed is TNFSF10; the disease is neoplasm.